Abstract
Background
Off-label use is the practice of prescribing a drug outside the terms of its official labeling. Worldwide, about 20% of the commonly prescribed medications are off-label, and the percentage increases in specific patient populations, such as children, pregnant women, and cancer patients. Off-label use is particularly widespread in oncology for many reasons, including the wide variety of cancer subtypes, the difficulties involved in performing clinical trials, the rapid diffusion of preliminary results, and delays in the approval of new drugs by regulatory organizations/agencies.
Objective
The aim of this article is to describe the use of off-label drugs in oncology, with an emphasis on the role of the world’s leading regulatory agencies and an assessment of current Italian legislation.
Conclusion
Off-label drug utilization is essential in oncology when based on evidence. However, off-label drugs must be prescribed in accordance with existing national laws and only when the potential benefit outweighs the potential toxic effects.
Similar content being viewed by others
References
Randall S, Stafford MD (2008) Regulating off-label drug use– rethinking the role of the FDA. N Engl J Med 358:1427–1429
De Souza JA (2011) Off-label drug utilization in oncology. Clin Adv Hematol Oncol 9:473–475
Conroy S, Newman C, Gudka S (2003) Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children. Ann Oncol 14:42–47
Brosgart CL, Mitchell T, Charlebois E et al (1996) Off-label drug use in human immunodeficiency virus disease. J Acquir Immune Defic Syndr Hum Retrovirol 12:56–62
Choonara I, Conroy S (2002) Unlicensed and off-label drug use in children: implications for safety. Drug Saf 25:1–5
Rayburn WF, Turnbull GL (1995) Off-label drug prescribing on a state university obstetric service. J Reprod Med 40:186–188
Stone KJ, Viera AJ, Parman CL (2003) Off-label applications for SSRIs. Am Fam Physician 68:498–504
Mortenson LE (1991) The off-label debate: a threat to the future of cancer care. Cancer Investig 9:597–599
The American Cancer Society: Off-label drug use. Available at: http://www.cancer.org/Treatment/TreatmentsandSideEffects/TreatmentTypes/Chemotherapy/off-label-drug-use. (Last Medical Review: March 14, 2011)
Levêque D, Michallat AC, Schaller C, Ranc M (2005) Off label drug use in adult patients treated by anticancer chemotherapy. Bull Cancer 92:498–500
Poole SG, Dooley MJ (2004) Off-label prescribing in oncology. Support Care Cancer 12:302–305
Dean-Colombo W, Fang S, Smith W et al (2009) Off-label drug use in women with breast cancer. J Clin Oncol 27[15 suppl]:abstract 1016
Kocs D, Fendrick AM (2003) Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. Am J Manag Care 9:393–400
Roila F, Ballatori E, Labianca R et al (2009) Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multi center survey. Tumori 95:647–651
Updated priority list for studies into off-patent pediatric medicinal products. European Medicines Agency: EMA/480197/2010. Available at:http://www.ema.europa.eu/docs/en_GB/library/Other/2009/10/WC500004017.pdf. Accessed 15 Sept 2011
Trotta F, Leufkens HGM, Schellens JHM et al (2011) Evaluation of oncology drugs at the European medicines agengy and US food and drug administration: when differences have an impact on clinical practice. J Clin Oncol 29:2266–2272
Drummond M, Mason A (2009) Rationing new medicines in the UK. Br Med J 338:a3182
Mason A, Drummond M, Ramsey S et al (2010) Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J Clin Oncol 28:3234–3238
Mason AR, Drummond MF (2009) Public funding of new cancer drugs: is NICE getting nastier? Eur J Cancer 45:1188–1192
Duran-Garcia E, Santos-Ramos B, Puigventos-Latorre F, Ortega (2011) A role of the hospital pharmacy and therapeutics committee in detecting and regulating off-label drug use, reply to letter. Int J Clin Pharm [Epub ahead of print]
Assises de médicament Groupe 3 “Encadrer les prescriptions hors AMM” (2011). Dispositifs dérogatoires de prescription “hors AMM”. Available at: http://www.sante.gouv.fr/IMG/pdf/Dispositifs_derogatoires_de_prescription_hors_AMM_.pdf. Accessed 15 Sept 2011
Agenzia Italiana del Farmaco (2007) Registro Farmaci Oncologici sottoposti a monitoraggio, Rapporto 2007. Available at http://antineoplastici.agenziafarmaco.it/Registro_farmaci.pdf. Accessed 15 Sept 2011
American Society of Clinical Oncology (2006) Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol 24:3206–3208
Levêque D (2008) Off-label use of anticancer drugs. Lancet Oncol 9:1102–1107
Bach PB (2009) Limits on Medicare’s ability to control rising spending on cancer drugs. N Engl J Med 360:626–633
Mullins CD, Montgomery R, Tunis R (2010) Uncertainty in assessing value of oncology treatments. Oncologist 15:58–64
Weißbach L, Riese J (2006) Off-label use in oncology: an inexhaustible topic? Urologe A 45(11):1410–1414
Baldwin J (2002) Demand grows for early access to promising cancer drugs. J Natl Cancer Inst 94:1668–1670
Romond EH, Perez EA, Bryan J, Suman VJ et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer. N Engl J Med 353:1673–1684
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672
Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676
Kramer BS, Hagerty KL, Justman S et al (2009) Use of 5-α-Reductase inhibitors for prostate cancer chemoprevention: American Society of clinical Oncology/American Urological association 2008 clinical practice guideline. J Clin Oncol 27:1502–1516
Andriole GL, Bostwick D, Brawley OW et al (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192–1202
Casali PG (2007) The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 18:1923–1925
Gazarian M, Kelly M, McPhee JR et al (2006) Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 185:544–548
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lerose, R., Musto, P., Aieta, M. et al. Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. Eur J Clin Pharmacol 68, 505–512 (2012). https://doi.org/10.1007/s00228-011-1173-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-011-1173-6